Analytical Data
-
基因名
HRASLS
- Application
-
别名
PLAAT1; HRASLS; Phospholipase A and acyltransferase 1; EC 2.3.1.-; EC 3.1.1.32; EC 3.1.1.4; HRAS-like suppressor 1; HRSL1; Phospholipid-metabolizing enzyme A-C1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9HDD0
-
表达区间
1-168aa
-
氨基酸序列
MAFNDCFSLNYPGNPCPGDLIEVFRPGYQHWALYLGDGYVINIAPVDGIPASFTSAKSVFSSKALVKMQLLKDVVGNDTYRINNKYDETYPPLPVEEIIKRSEFVIGQEVAYNLLVNNCEHFVTLLRYGEGVSEQANRAISTVEFVTAAVGVFSFLGLFPKGQRAKYY
-
分子量
45.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HRASLS (HRAS-like suppressor) proteins are a family of enzymes that have garnered attention due to their potential roles in cellular processes and disease mechanisms. Initial studies suggested that HRASLS proteins act as lipid phosphate phosphohydrolases, implicating them in the regulation of lipid signaling pathways. Given their structural similarity to the HRAS oncogene, researchers are particularly interested in understanding how HRASLS may influence cancer progression and other diseases linked to dysregulated cell signaling. Recent evidence indicates that these proteins can modulate processes such as proliferation, apoptosis, and differentiation, positioning them as potential biomarkers or therapeutic targets in various cancers. Furthermore, HRASLS expression levels have been correlated with different cancer types, offering insights into their potential as prognostic indicators. Continued investigation into the biochemical properties and regulatory mechanisms of HRASLS proteins may reveal novel strategies for intervention in diseases characterized by aberrant signaling pathways, thus highlighting their relevance in both basic and applied biomedical research.
